As the House Energy and Commerce Committee prepares to consider a legislative provision (H.R. 3561) that would reduce payments for drug administration services furnished in off-campus provider-based departments, the AHA and other national hospital groups reiterated to committee leaders their opposition to the proposal and to site-neutral policies in general, which fail to account for the fundamental differences between hospital outpatient departments (HOPDs) and other ambulatory care sites. 

“It is important to note that HOPDs treat patients who are sicker and have more chronic conditions than those treated in physician offices or ambulatory surgical centers, as they are better equipped to handle complications and emergencies,” the letter notes. The committee is scheduled to consider H.R. 3561 tomorrow.

AHA also released a fact sheet highlighting three site-neutral proposals being considered by the committee and their estimated impact on Medicare reimbursement to hospitals and health systems; the estimates should not be combined because the legislative proposals contain some overlap. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services released a memo Dec. 16 announcing the agency’s intent to conduct a voluntary pilot in 2026, called the…
Headline
The Centers for Medicare & Medicaid Services Dec. 15 published the Measures Under Consideration List for 2025. These are measures that CMS is considering…
Headline
The Medicare Payment Advisory Commission Dec. 4 and 5 discussed draft payment update recommendations for 2027, which the commission will vote on in January.…
Headline
The House Dec. 1 passed the Hospital Inpatient Services Modernization Act (H.R. 4313), legislation extending certain Medicare waivers authorizing the hospital-…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 1 that it intends to expand the Inpatient Rehabilitation Facility Review Choice Demonstration…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…